The UK and US have agreed to a key trade agreement that will keep no tariffs on UK pharmaceutical exports going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the NHS. This pledge guarantees that duties on these vital exports will remain at zero for a timeframe of the next three years.
This development is in response to earlier warnings to dramatically increase duties on branded pharmaceutical imports, with increases floated reaching one hundred percent.
"This agreement between the UK bolsters the global environment for innovative medicines and establishes much-needed fairness to American-British pharmaceutical trade," an announcement said.
Trade Impact
Drugs represent one of the Britain's biggest export categories to the US, which is by far the largest destination for major UK drugmakers.
Trade data indicate that in the 12 months to the end of last September, the UK shipped medicines totaling over eleven billion pounds to the US. This value accounted for a significant portion of all goods exports in that span.
"This agreement secures jobs, boosts investment and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement entails several key commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to double total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Recent Tensions
This agreement comes amid a long-running dispute between the sector and the UK government over drug pricing and approval rates.
This friction were intensified by claims that US patients were paying a premium for the identical medicines than people in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.
